Topic
Solid lipid nanoparticle
About: Solid lipid nanoparticle is a research topic. Over the lifetime, 3175 publications have been published within this topic receiving 127912 citations. The topic is also known as: LNP & SLN.
Papers published on a yearly basis
Papers
More filters
Patent•
05 Mar 2012
TL;DR: In this article, solid lipid nanoparticles and the process thereof are disclosed, which include: at least one lipid selected from the group consisting of glycerides and fatty acids, at least a hydrophilic drug or amphiphilic drug and at least an emulsifier.
Abstract: Solid lipid nanoparticles and the process thereof are disclosed. The solid lipid nanoparticles comprise: at least one lipid selected from the group consisting of glycerides and fatty acids, at least one hydrophilic drug or amphiphilic drug and at least one emulsifier.
49 citations
TL;DR: It is indicated that the hydrophilic drug sumatriptan succinate, loaded in chitosan SLN, can be successfully targeted to brain via oral delivery and thus present an effective approach for the therapeutic management of migraine.
49 citations
TL;DR: It is demonstrated that SLN prepared by ultrasonication method is more suitable than microemulsion technique without causing any significant effect on corneal hydration level.
Abstract: Voriconazole is a second-generation antifungal agent with excellent broad spectrum of antifungal activity commercially available for oral and intravenous administration. Systemic administration of voriconazole is associated with side effects including visual and hepatic abnormalities. This study assessed the feasibility of using solid lipid nanoparticles for ocular delivery of voriconazole adopting stearic acid as lipidic material, tween 80 as a stabilizer, and Carbopol 934 as controlled release agent and for increasing the precorneal residence time in eye. The systems were prepared using two different methods, that is, ultrasonication method and microemulsion technique. The results indicated that the larger particle size of SLNs was found with microemulsion technique ( nm to ) compared to SLN prepared with ultrasonication method ( nm to nm). The polydispersity index values were less than 0.3 for all formulations and zeta potential of the prepared formulations by these two methods varied from − mV to − mV. Powder X-ray diffraction and differential scanning calorimetry indicated decrease in crystallinity of drug. The in vitro release study and the SLN formulations prepared with ultrasonication method demonstrated sustained release up to 12 hours. This study demonstrated that SLN prepared by ultrasonication method is more suitable than microemulsion technique without causing any significant effect on corneal hydration level.
49 citations
TL;DR: The freeze-dried powders form could enhance the long-term stability of SLN, and solid lipid nanoparticles encapsulation could effectively strategy to change the poor aqueous solubility and prolong the half-life of GNA.
49 citations
TL;DR: The biopharmaceutical challenges in oral cancer chemotherapy are discussed and how Lipid nanoparticles (LNPs) may provide solutions to such challenges.
Abstract: Chemotherapeutic delivery by oral route in cancer patients has the potential to create "hospitalization free chemotherapy" which is a vision of oncologists, formulation scientists and patients. Such a therapeutic approach will improve patients' compliance, ease the burden of the patients' caregivers and significantly reduce the cost of treatment. In current clinical practice, chemotherapy carried out by intravenous injection or infusion leads to undesired side-effects such as plasma concentrations crossing the maximum safe concentration, rapid body clearance and lower bioavailability. Despite the presence of challenges such as poor aqueous solubility and stability of drugs and the presence of biological barriers like multidrug efflux transporter in the GI tract, oral cancer chemotherapy has the potential to surmount those obstacles. Lipid nanoparticles (LNPs) such as solid lipid nanoparticle, nanostructured lipid carriers, nano lipid-drug conjugates, mixed micelles, liposomes and nanoemulsions have shown some promising results for use in oral anticancer drug delivery through nanotechnological approach. LNPs demonstrate enhanced oral bioavailability owing to their ability to inhibit first pass metabolism via lymphatic absorption by chylomicron-linked and/or M-cell uptake. LNPs reduce the inter- and intrasubject pharmacokinetics variability of administrated drugs. Moreover, certain classes of phospholipids and surfactants used in the formulations of LNPs can suppress the P-glycoprotein efflux system. Here, we shall be discussing the biopharmaceutical challenges in oral cancer chemotherapy and how the LNPs may provide solutions to such challenges. The effect of GI tract environment on LNPs and pharmacokinetics shall also be discussed.
49 citations